Vaccine Effectiveness, Burden and Impact Studies (VEBIS) of COVID-19 and Influenza

Project description

The objectives of the project is to provide technical support to the European Center for Disease Prevention and Control to build an infrastructure to allow regular monitoring of COVID-19 and influenza vaccine effectiveness over time, using a multi-country approach. The VEBIS platform includes vaccine effectiveness studies implemented in different settings.

Context situation

Vaccination plays a key role in the control of the coronavirus disease (COVID-19) pandemic and the lifting of some non-pharmaceutical interventions. Assessment of the real-world performance of the vaccines in the European Union is important to be able to adapt to European vaccination strategies.

Project activities

Hospital network measuring influenza and COVID-19 vaccine effectiveness

Multicenter test-negative design study.

Vaccine effectiveness and impact of COVID-19

vaccines through routinely collected exposure and outcome data using health registries.

COVID-19 vaccine effectiveness against SARS-CoV-2 infection among healthcare workers

Multicenter cohort study.

Primary care network measuring influenza and COVID-19 vaccine effectiveness

Multicenter test-negative design study.

Scientific publications

Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to SARS-CoV-2 in individuals aged 20 years and older – fourth update

Jennifer Howard, Esther Kissling, Ruoran Li, Anthony Nardone, Angie Rose (Epiconcept)

ECDC: Stockholm; 2023 March, 16

Available here

Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalization with Severe Acute Respiratory Infection, laboratoryconfirmed with SARS-CoV-2 or with seasonal influenza – Version 2.0

Jenny Howard, Esther Kissling, Ruoran Li, Alain Moren, Anthony Nardone, Angie Rose, Marta Valenciano (Epiconcept)

Stockholm: ECDC; 2023.January

Available here

European Center for Disease Prevention and Control. Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 20 years and older, ECDC multi-country study – third update

European Center for Disease Prevention and Control: Sabrina Bacci, Nathalie Nicolay.
Epiconcept, Paris, France: Jennifer Howard, Esther Kissling, Anthony Nardone, Angie Rose

ECDC: Stockholm; 2022 November 8.

Available here

COVID-19 vaccine effectiveness among healthcare workers in Albania (COVE-AL): protocol for a prospective cohort study and cohort baseline data.

Sridhar S, Fico A, Preza I, Hatibi I, Sulo J, Kissling E, Daja R, Ibrahim R, Lemos D, Rubin-Smith J, Schmid A, Vasili A, Valenciano M, Jorgensen P, Pebody R, Lafond KE, Katz MA, Bino S.

BMJ Open 2022;12:e057741. doi:10.1136/bmjopen-2021-057741

Available here

European Center for Disease Prevention and Control. Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update.

European Center for Disease Prevention and Control.

ECDC: Stockholm; 2022 January 20

Available here

Estimate of COVID-19 vaccine effectiveness against hospitalization in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022

Sentis A, Kislaya I, Nicolay N, Meijerink H, Starrfelt J, Martínez-Baz I, Castilla J, Nielsen KF, Hansen CH, Emborg HD, Nardone A, Derrough T, Valenciano M, Nunes B, Monge S, the VEBIS-Lot4 working group

October 2021 to March 2022. Euro Surveillance. 2022;27(30):pii=2200551

Available here

European Center for Disease Prevention and Control. Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – second update.

European Center for Disease Prevention and Control.

ECDC: Stockholm; 2022 Mar, 14.

Available here

Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicenter analysis, I-MOVE-COVID-19 and ECDC networks

Kissling E, Hooiveld M, Martínez-Baz, Mazagatos C, William N, Vilcu AM, Kooijman MN, Ilić M, Domegan L, Machado A, de Lusignan S, Lazar M, Meijer A, Brytting M, Casado I, Larrauri A, Murray JL K, Behillil S, de Gier B, Mlinarić I, O'Donnell J, Rodrigues AP, Tsang R, Timnea O, de Lange M, Riess M, Castilla J, Pozo F, Hamilton M, Falchi A, Knol MJ, Kurečić Filipović S, Dunford L, Guiomar R, Cogdale J, Cherciu C Jansen T, Enkirch T, Basile L, Connell J, Gomez V Sandonis Martín V, Bacci S, Rose AMC, Pastore Celentano L, Valenciano M, I-MOVE-COVID-19 and ECDC primary care study teams

July to August 2021. Euro Surveillance. 2022;27(21):pii=2101104

Available here

European Center for Disease Prevention and Control.

ECDC: Stockholm; 2021 October, 8.

Available here

Core protocol for ECDC studies of COVID19 vaccine effectiveness against hospitalization with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2, version 1.0. Stockholm: ECDC; 2021 Oct, 8.

Available here

Find all our scientific publications

Vaccine Effectiveness, Burden and Impact Studies (VEBIS) of COVID-19 and Influenza

Project description

Context situation

Project activities

Hospital network measuring influenza and COVID-19 vaccine effectiveness

Vaccine effectiveness and impact of COVID-19

COVID-19 vaccine effectiveness against SARS-CoV-2 infection among healthcare workers

Primary care network measuring influenza and COVID-19 vaccine effectiveness

Scientific publications

Central purchasing referencing

Health data hosting

Commitment and ethics